prikaz prve stranice dokumenta Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa
  Download
PDF 1.24 MB
Scientific paper - Original scientific paper
Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa
PLoS ONE, 10 (2015), 3; e0120981. https://doi.org/10.1371/journal.pone.0120981
Hampson, Lisa V.; Whitehead, John; Eleftheriou, Despina; Tudur-Smith, Catrin; Jones, Rachel; Jayne, David; Hickey, Helen; Beresford, Michael W.; Bracaglia, Claudia; Caldas, Afonso; Cimaz, Rolando; Dehoorne, Joke; Dolezalova, Pavla; Friswell, Mark; Jelušić, Marija; Marks, Stephen D.; Martin, Neil; McMahon, Anne-Marie; Peitz, Joachim; van Royen-Kerkhof, Annet; Soylemezoglu, Oguz; Brogan, Paul A. More authors...

Cite this document

Hampson, L. V., Whitehead, J., Eleftheriou, D., Tudur Smith, C., Jones, R., Jayne, D. ... Brogan, P. A. (2015). Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa. PLoS ONE, 10. (3). doi: 10.1371/journal.pone.0120981

Hampson, Lisa V., et al. "Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa." PLoS ONE, vol. 10, no. 3, 2015. https://doi.org/10.1371/journal.pone.0120981

Hampson, Lisa V., John Whitehead, Despina Eleftheriou, Catrin Tudur Smith, Rachel Jones, David Jayne, Helen Hickey, et al. "Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa." PLoS ONE 10, no. 3 (2015). https://doi.org/10.1371/journal.pone.0120981

Hampson, L. V., et al. (2015) 'Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa', PLoS ONE, 10(3). doi: 10.1371/journal.pone.0120981

Hampson LV, Whitehead J, Eleftheriou D, Tudur Smith C, Jones R, Jayne D, and sur.. Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa. PLoS ONE [Internet]. 2015 March 30 [cited 2024 October 07];10(3). doi: 10.1371/journal.pone.0120981

L. V. Hampson, et al., "Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa", PLoS ONE, vol. 10, no. 3, March 2015. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:148094. [Accessed: 07 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa
AuthorLisa V. Hampson
AuthorJohn Whitehead
AuthorDespina Eleftheriou
AuthorCatrin Tudur-Smith
AuthorRachel Jones
AuthorDavid Jayne
AuthorHelen Hickey
AuthorMichael W. Beresford
AuthorClaudia Bracaglia
AuthorAfonso Caldas
AuthorRolando Cimaz
AuthorJoke Dehoorne
AuthorPavla Dolezalova
AuthorMark Friswell
AuthorMarija Jelušić
AuthorStephen D. Marks
AuthorNeil Martin
AuthorAnne-Marie McMahon
AuthorJoachim Peitz
AuthorAnnet van Royen-Kerkhof
AuthorOguz Soylemezoglu
AuthorPaul A. Brogan
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
OBJECTIVES: Definitive sample sizes for clinical trials in rare diseases are usually infeasible. Bayesian methodology can be used to maximise what is learnt from clinical trials in these circumstances. We elicited expert prior opinion for a future Bayesian randomised controlled trial for a rare inflammatory paediatric disease, polyarteritis nodosa (MYPAN, Mycophenolate mofetil for polyarteritis nodosa). ----- METHODS: A Bayesian prior elicitation meeting was convened. Opinion was sought on the probability that a patient in the MYPAN trial treated with cyclophosphamide would achieve disease remission within 6-months, and on the relative efficacies of mycophenolate mofetil and cyclophosphamide. Expert opinion was combined with previously unseen data from a recently completed randomised controlled trial in ANCA associated vasculitis. ----- RESULTS: A pan-European group of fifteen experts participated in the elicitation meeting. Consensus expert prior opinion was that the most likely rates of disease remission within 6 months on cyclophosphamide or mycophenolate mofetil were 74% and 71%, respectively. This prior opinion will now be taken forward and will be modified to formulate a Bayesian posterior opinion once the MYPAN trial data from 40 patients randomised 1:1 to either CYC or MMF become available. ----- CONCLUSIONS: We suggest that the methodological template we propose could be applied to trial design for other rare diseases.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titlePLoS ONE
Numberingvol. 10, no. 3, e0120981
p-ISSN1932-6203
DOIhttps://doi.org/10.1371/journal.pone.0120981
URN:NBNurn:nbn:hr:105:148094
Publication2015-03-30
Document URLhttps://doi.org/10.1371/journal.pone.0120981
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 08:11:41